CDK6 and neoplasm: To verify the differential expression status between CDK6 and LRP1B in patients with (study group) or without (control group) mutations, we performed IHC staining on tumor tissues from 36 and 34 patients, who were screened and matched using tNGS, from the CDK6 and LRP1B groups, respectively.